TrialLeukemia2022

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.

Tim H Brümmendorf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.